兰伯西起步于1937年日本原野义制药的分销商Ranjit Singh和 Gurbax Singh。有趣的是，Ranbaxy的名称是个混合词，取自于最初的所有者Ranjit 和Gurbax。Bhai Mohan Singh的儿子 Parvinder Singh于1967年入主公司后，公司的商业模式发生了重大改变。颇具讽刺意味的是，2008年6月，他的儿子Malvinder Mohan Singh 和Shivinder Mohan Singh又将其公司卖给了日本人，完成了一个轮回。
[edit] Markets（市场）
In 1998, Ranbaxy entered the United States of America, the world's largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005.
1998年，兰伯西进入美国市场，世界上最大的医药市场，也是目前兰伯西的最大市场，2005年占兰伯西销售额的28%。
For the twelve months ending on December 31, 2005, the company's global sales were at US $1,178 million with overseas markets accounting for 75% of global sales (USA: 28%, Europe: 17%, Brazil, Russia, and China: 29%). For the twelve months ending on December 31, 2006, the company's global sales were at US $1,300 million.
公司2005年的总销售额为11.78亿美元，其中海外市场占75%（USA28%，Europe17%，Brazil, Russia, and China: 29%)。2006年的销售总额为13亿美元。
Most of Ranbaxy's products are manufactured by license from foreign pharmaceutical developers, though a significant percentage of their products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired.
许多兰伯西的产品被医药开发商许可生产，尽管其中很大比例的产品是非专利药，这些产品的生产和分销不需要获得原研厂家的许可，因为这些药品的专利已经过期。
In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion. [1]
2005年12月，兰伯西的股票因为专利问题遭受挫折，欲仿制辉瑞的降胆固醇药立普妥没有成功，该产品的年销售额超过100亿美元。
On June 23, 2006, Ranbaxy received from the U.S. Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug at 80 mg strength. Ranbaxy presently competes with the maker of brand-name Zocor, Merck & Co.; Teva Pharmaceutical Industries, which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories, also from India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
2006年6月23日，兰伯西获得FDA批准，答应在美国市场销售舒降之的80mg规格的仿制药辛伐他汀，并获得180天的独占期。兰伯西开始与品牌药舒降之生产厂家默克公司竞争市场，梯瓦公司也获得了除80mg规格以外的180天的独占期，而同样来自印度的阮氏公司由于获得默克的授权仿制而不受限制。

[edit] Acquisition收购
On June 10, 2008, Japan's Daiichi Sankyo Co., agreed to take a majority (50.1%) stake in Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction. [2]
2008年6月10日，日本第一三共株氏会社出资46亿美元同意收购兰伯西50.1%的股权。Malvinder Mohan Singh将在交易后继续担任CEO。

共6页: 上一页 [1] [2] [3] [4] [5] 6 下一页